The Journal of asthma : official journal of the Association for the Care of Asthma · 2026
Clinical utility of pentraxin-3 and eosinophil-derived neurotoxin as biomarkers of disease activity in pediatric bronchial asthma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abd-Elmawgood Eman Ahmed, Abdallah Ahmed Alamir Mahmoud, Hassan Mohammed H, Abo El-Hasan Marwa Nasr, Hm Fayed, Rashwan Nagwan I
Аннотация
BACKGROUND: Bronchial asthma is a chronic inflammatory airway disorder driven predominantly by Th2-mediated immune responses and eosinophilic activation. Eosinophil-derived neurotoxin (EDN) and pentraxin-3 (PTX3) have been implicated in airway inflammation and remodeling, yet their clinical relevance in children is not fully established.
OBJECTIVES: To assess serum EDN and PTX3 levels in children with bronchial asthma compared with healthy controls, and to evaluate their diagnostic performance and association with asthma severity and control.
METHODS: This case-control study included 105 Egyptian children aged 2-18 years (55 asthmatics and 50 healthy controls). Asthma diagnosis, severity, and control were classified according to Global Initiative for Asthma (GINA) guidelines. All participants underwent detailed clinical evaluation, chest radiography, spirometry, and laboratory investigations, including serum EDN, and PTX3 measured by ELISA.
RESULTS: Serum EDN and PTX3 levels were significantly elevated in asthmatic children compared with controls (p < 0.0001). EDN showed significant correlations with eosinophil count, IgE, exacerbation frequency, and pulmonary function indices, whereas PTX3 demonstrated weaker clinical associations. ROC analysis showed good discriminatory ability for EDN (AUC = 0.82) and high discrimination for PTX3 (AUC = 0.91) between asthmatic and non-asthmatic subjects, but limited ability of PTX3 to stratify asthma control.
CONCLUSION: EDN and PTX3 are associated with pediatric asthma, reflecting different components of airway inflammation. EDN demonstrated closer relationships with markers of disease activity suggesting its potential role as an adjunct biomarker for monitoring inflammation, while PTX3 primarily differentiated asthmatic from healthy children. These biomarkers should be considered complementary research tools rather than stand-alone diagnostic tests.
OBJECTIVES: To assess serum EDN and PTX3 levels in children with bronchial asthma compared with healthy controls, and to evaluate their diagnostic performance and association with asthma severity and control.
METHODS: This case-control study included 105 Egyptian children aged 2-18 years (55 asthmatics and 50 healthy controls). Asthma diagnosis, severity, and control were classified according to Global Initiative for Asthma (GINA) guidelines. All participants underwent detailed clinical evaluation, chest radiography, spirometry, and laboratory investigations, including serum EDN, and PTX3 measured by ELISA.
RESULTS: Serum EDN and PTX3 levels were significantly elevated in asthmatic children compared with controls (p < 0.0001). EDN showed significant correlations with eosinophil count, IgE, exacerbation frequency, and pulmonary function indices, whereas PTX3 demonstrated weaker clinical associations. ROC analysis showed good discriminatory ability for EDN (AUC = 0.82) and high discrimination for PTX3 (AUC = 0.91) between asthmatic and non-asthmatic subjects, but limited ability of PTX3 to stratify asthma control.
CONCLUSION: EDN and PTX3 are associated with pediatric asthma, reflecting different components of airway inflammation. EDN demonstrated closer relationships with markers of disease activity suggesting its potential role as an adjunct biomarker for monitoring inflammation, while PTX3 primarily differentiated asthmatic from healthy children. These biomarkers should be considered complementary research tools rather than stand-alone diagnostic tests.